Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Key Highlights
- ➤November 4 KOL event will address NF1 cutaneous and plexiform neurofibroma treatment needs
- ➤PAS-004 is being tested in Phase 1 advanced cancer trial NCT06299839
- ➤PAS-004 is being tested in Phase 1/1b adult NF1 plexiform neurofibroma trial NCT06961565
- ➤Management will review Phase 1 solid tumor data presented at ESMO Congress 2026
- ➤Pasithea will summarize PAS-004’s commercial opportunity across both NF1 manifestations
Expert Statements
Rebecca M. Brown, Associate Professor of Neurology, University of Alabama at Birmingham Heersink School of Medicine
“Her experience spans NF laboratory research and clinical trials, including studies involving the RAS-RAF-MEK-ERK (MAPK) pathway.”
Kavita Sarin, Professor of Dermatology and Director of the Stanford Skin Cancer Genetics Program, Stanford Cancer Institute
“Her research focuses on precision medicine, integrating genetic and clinical information to understand disease susceptibility, prognosis, and treatment in skin cancer and rare dermatologic disorders.”
Kavita Sarin, Professor of Dermatology and Director of the Stanford Skin Cancer Genetics Program, Stanford Cancer Institute
“Dr. Sarin co-leads the Cutaneous Neurofibroma Working Group within the Response Evaluation in Neurofibromatosis & Schwannomatosis (REiNS) collaboration, advancing international efforts to develop core outcome sets, patient-reported outcome measures, and standardized clinical trial endpoints for NF1.”
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, for the long-term treatment of chronic diseases including neurofibromatosis type 1 (NF1) associated neurofibromas, today announced that it will host a virtual key opinion leader (KOL) event, “Rethinking NF1 Treatment: KOL Perspectives on Cutaneous and Plexiform Neurofibromas,” on Wednesday, November 4, 2026, at 11:00 a.m. ET.
The event will feature Rebecca M. Brown, MD, Associate Professor of Neurology at the University of Alabama at Birmingham (UAB), Heersink School of Medicine, and Kavita Sarin, MD, PhD, Professor of Dermatology and Director of the Stanford Skin Cancer Genetics Program at the Stanford Cancer Institute. The KOLs will join company management to discuss unmet medical needs and the current treatment landscape for neurofibromatosis type 1 (NF1)-associated cutaneous neurofibromas (CN) and plexiform neurofibromas (PN).
Get started
Create a free account to read the full story.